Soleimani E, Ahmadiani A, Bazrgar M, Khodagholi F, Eliassi A. The 40-Hz White Light Emitting Diode to Alleviate Psychiatric Symptoms Induced by Streptozotocin In Vivo.
Basic Clin Neurosci 2024;
15:463-476. [PMID:
39553262 PMCID:
PMC11565670 DOI:
10.32598/bcn.2024.1856.1]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2024] [Revised: 01/15/2024] [Accepted: 01/16/2024] [Indexed: 11/19/2024] Open
Abstract
Introduction
A 40-Hz white light emitting diode (WLED) has emerged as an alternative nonpharmacological and noninvasive approach to Alzheimer disease (AD). Here, we investigated the therapeutic effects of 40-Hz WLED on psychiatric symptoms (PS) and the contribution of mitochondrial factors in the early stages of sporadic AD (sAD) in rats.
Methods
In male Wistar rats, the AD model was induced via intracerebroventricular (ICV) injection of streptozotocin (STZ). After recovering (7 days) from stereotaxic surgery, 40-Hz WLED exposure was performed for 7 consecutive days lasting 15 min/d. Behavioral (elevated plus maze (EPM), force swim test, and social interaction test), enzymatic, and molecular assays were conducted 24 hours after the last 40-Hz WLED exposure.
Results
Behavioral tasks revealed that 40-Hz WLED exposure in STZ-induced toxicity rats lowered anxiety and depression and increased social interaction. Furthermore, the 40-Hz WLED therapy in STZ-induced toxicity rats increased catalase (CAT) activity in the amygdala, decreased the activity of monoamine oxidases A and B in the whole brain, and increased mitochondrial DNA in the hippocampus.
Conclusion
The current study supports that 40-Hz WLED therapy improved PS and biomarkers in the early stages of sAD. Also, a potential relationship between PS and alterations in mitochondrial markers in certain brain regions seems to exist.
Collapse